CHP
  • CHP Home
  • About
  • Opportunities
  • Clients
  • BD&L Services
  • Contact CHP
  • Search
  • Menu Menu
  • LinkedIn
in505(b)(2), In-licensing, Opportunities

505(b)(2) formulation for schizophrenia available for in-licensing:

CHP is pleased to announce the availability

  • 505(b)(2) formulation for the treatment of schizophrenia.
  • Approval expected in late 2021.
  • This is an oral dissolving agent.  Abilify is the original molecule.

See Below for More

in505(b)(2), In-licensing, Opportunities

505(b)(2) formulation for chemotherapy available in-licensing

October 26, 2021
505(b)(2) formulation for the treatment of chemotherapy induced nausea and vomiting. Multiple advantages over currently available products including the ability to use without further reconstitution.
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png 300 300 Jim Usry https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png Jim Usry2021-10-26 15:52:272021-10-31 18:41:20505(b)(2) formulation for chemotherapy available in-licensing

505(b)(2) formulation for schizophrenia available in-licensing

October 26, 2021
505(b)(2) formulation for schizophrenia available for in-licensing:
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png 300 300 Jim Usry https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png Jim Usry2021-10-26 15:47:292021-10-31 18:41:41505(b)(2) formulation for schizophrenia available in-licensing

Approved 505(b)(2) available for in-licensing

August 17, 2021
Approved 505(b)(2) available for in-licensing: CHP is pleased to announce the availability of an approved 505(b)(2) product in the cardiovascular space. US rights only.
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png 300 300 Jim Usry https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png Jim Usry2021-08-17 15:44:022021-10-31 18:42:01Approved 505(b)(2) available for in-licensing

Chemotherapy induced nausea and vomiting product available for in-licensing

https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/In-License-icon.png 300 300 Jim Usry https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png Jim Usry2020-10-10 15:36:022021-10-31 18:07:59Chemotherapy induced nausea and vomiting product available for in-licensing

Schizophrenia asset available for in-licensing

September 20, 2020
505(b)(2) product for the treatment of schizophrenia available for in-licensing. Multiple markets available including the US. NDA filed in the US in 2019. Approval expected in 2021.
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/In-License-icon.png 300 300 Jim Usry https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png Jim Usry2020-09-20 15:05:132021-10-31 18:08:31Schizophrenia asset available for in-licensing
PreviousNext

  • 505(b)(2) (3)
  • Opportunities (13)
    • In-licensing (5)
    • Manufacturing (7)
  • Phase 3 (1)

Questions? Feel free to contact us!

Call (615) 887-3847

We appreciate your interest!  Please get in touch and we will contact you directly.

Services and Partnership Opportunities

  • Pharmaceutical BD&L
  • Pharma BD&L
  • Pharmaceutical business development
  • ANDAs for sale
  • ANDA licensing
  • Pharmaceutical in-licensing
  • Pharmaceutical out-licensing
  • 505(b)(2) for sale
  • Pharma in-licensing
  • Pharma out-licensing
  • Oncology company for sale
  • Oncology sales force
  • Pharma distribution deals
  • Branded generics for sale
  • Pharmaceutical partnering companies
  • Pharmaceutical development deals
  • Pharma commercialization consulting
  • Head and neck cancer assets available for licensing
  • Pharmaceutical deal arrangers
  • Pharma manufacturing facilities finders
  • Pharmaceutical authorized generic products available

 

Commercial Healthcare Partners

DISCLAIMER

The information contained in this website is for general information purposes only. The information is provided by Commercial Healthcare Partners and while we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

About | Services| Contact | Privacy Policy

Copyright © 2021 - - Commercial Healthcare Partners LLC - NJ Website Design & Development - Birchwood Group
  • LinkedIn
Oral Solid Dose (OSD) Tablets & Capsules facility Sale505(b)(2) formulation for chemotherapy available in-licensing
Scroll to top